secwatch.observer — SEC 8-K summary
======================================

Issuer:     Monte Rosa Therapeutics, Inc. (GLUE)
CIK:        0001826457
Form:       8-K
Filed at:   2025-08-07T23:59:59+00:00
Accession:  0000950170-25-104545
Event type: earnings
Sentiment:  positive
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Monte Rosa Q2 net loss narrows to $12.3M on $23.2M collaboration revenue; cash runway to 2028
--------------------------------------------------------------------------------

- Collaboration revenue $23.2M (vs $4.7M YoY) from Novartis license; net loss improved to $12.3M from $30.3M.
- R&D $30.7M, G&A $8.1M; cash $295.5M (down $35.5M from Q1), expected to fund into 2028.
- Phase 1 of NEK7-directed MGD MRT-8102 dosed; initial data expected H1 2026 for inflammatory diseases.
- MRT-6160 advancing toward multiple Phase 2 studies with Novartis; potential milestones up to $2.1B.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1826457/000095017025104545/0000950170-25-104545-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1826457/000095017025104545/glue-20250807.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-104545

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer